GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARS Pharmaceuticals Inc (NAS:SPRY) » Definitions » Sale Of Property, Plant, Equipment

SPRY (ARS Pharmaceuticals) Sale Of Property, Plant, Equipment : $0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is ARS Pharmaceuticals Sale Of Property, Plant, Equipment?

ARS Pharmaceuticals's sale of property, plant, equipment for the three months ended in Dec. 2024 was $0.00 Mil. It means ARS Pharmaceuticals gained $0.00 Mil from selling property, plant, and equipment. ARS Pharmaceuticals's sale of property, plant, equipment for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

Compared with last quarter ($0.00 Mil in Sep. 2024 ), ARS Pharmaceuticals gained the same money from selling property, plant, and equipment in Dec. 2024 ($0.00 Mil).

ARS Pharmaceuticals Sale Of Property, Plant, Equipment Historical Data

The historical data trend for ARS Pharmaceuticals's Sale Of Property, Plant, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARS Pharmaceuticals Sale Of Property, Plant, Equipment Chart

ARS Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Sale Of Property, Plant, Equipment
- - - - -

ARS Pharmaceuticals Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Sale Of Property, Plant, Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ARS Pharmaceuticals Sale Of Property, Plant, Equipment Calculation

The amount earned to sell PPE.

Sale Of Property, Plant, Equipment for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ARS Pharmaceuticals Sale Of Property, Plant, Equipment Related Terms

Thank you for viewing the detailed overview of ARS Pharmaceuticals's Sale Of Property, Plant, Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.

ARS Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARS Pharmaceuticals Inc (NAS:SPRY) » Definitions » Sale Of Property, Plant, Equipment
Comparable Companies
OCUL ETNB VRDN ARDX IOVA LQDA DYN ADPT INVA AUPH VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
11682 El Camino Real, Suite 120, San Diego, CA, USA, 92130
Website
https://www.ars-pharma.com
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Executives
Laura Shawver director, officer: Chief Executive Officer 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Richard E Lowenthal director, 10 percent owner, officer: President and CEO 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Sarina Tanimoto 10 percent owner, officer: Chief Medical Officer C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Justin Chakma officer: Chief Business Officer C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Brian Dorsey officer: Chief Operating Officer C/O SOMAXON PHARMACEUTICALS, INC., 10935 VISTA SORRENTO PARKWAY, SUITE 250, SAN DIEGO CA 92130
Eric Karas officer: Chief Commercial Officer C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
James E Flynn director, 10 percent owner, other: Director by deputization 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Kathleen D. Scott officer: Chief Financial Officer C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter A. Thompson director C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Ra Capital Healthcare Fund Lp director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Alexander A Fitzpatrick officer: Chief Legal Officer 9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121
Orbimed Capital Gp Vi Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Brent L Saunders director 2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033
Rajeev Dadoo director C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130